Repros Therapeutics

Repros Therapeutics — Investor Presentation (June 2012)

37 slides from Repros Therapeutics's investor presentation, Jun 7, 2012

  1. Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders

    Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders

  2. Slide 2: Repros Disclaimer

    Repros Disclaimer Any statements that are not historical facts contained in this release are forward - looking statements that involve risks and uncertainties, including Repros ' ability to have the partial hold on Proellex ® lifted and to determine a safe and effective dose for Proellex ®, raise ne

  3. Slide 3: Investment Highlights

    Investment Highlights • Focused strategy: small molecule therapeutics for reproductive disorders • Two late stage clinical programs each with +$1B sales potential • Androxal ® : oral treatment for Low Testosterone with pending patent/ patent life to the mid 2020’s(growing +$1B market) – Restoration

  4. Slide 4: Testosterone Market Continues to Grow

    Testosterone Market Continues to Grow 0 200 400 600 800 1,000 1,200 1,400 1,600 1,800 1998 2000 2002 2004 2006 2008 2010 2012 $ millions • 2011 worldwide sales >$1.6B with 25% compound annual growth • US accounts for 75% of global sales • Major pharmaceutical companies have moved to capture US oppor

  5. Slide 5: Who are the men using testosterone?

    Who are the men using testosterone? European Male Aging Study Distribution and Selected Characteristics of Men Ages 40 - 79 ( Tajar et al) 0 10 20 30 40 50 60 70 80 90 100 Eugonadal Secondary Hypogonadal Primary Compensated Hypogonadism % of Subjects Age: 58.5 (10.7) BMI: 27.3 TT: 513.4 ng / dL LH:

  6. Slide 6: The Average American Male at All Ages Was Overweight in 2000

    The Average American Male at All Ages Was Overweight in 2000 22 23 24 25 26 27 28 29 30 20-29 30-39 40-49 50-59 60-74 BMI Age by Decade Mean BMI 1960 2000 Overweight BMI > 25 (6’ 190# male BMI=25.8) Obese BMI > 30 (6’ 230# male BMI =31.2) In 2010 there were ~90 million men in the US between the ages

  7. Slide 7: Secondary Hypogonadism

    Secondary Hypogonadism • Majority of men with low T have secondary hypogonadism • Results from a suppression of secretion of pituitary hormones – Obese men are estrogenized • LH & FSH secretions are low to low normal • Testosterone Levels <300ng/dl • Men with secondary h ypogonadism are typically s

  8. Slide 8: Approved T Replacement Products Shutdown Testicular Function

    Approved T Replacement Products Shutdown Testicular Function Testes Hypothalamus / Pituitary Axis • Pituitary secretions decrease or shut down • Testicular function decreases or shuts down • 30% of men castrated at the level of the pituitary Leydig Cell Activity Suppressed Spermatogenesis Suppressed

  9. Slide 9: Androxal Restores Normal Testicular Function

    Androxal Restores Normal Testicular Function Testes Increased T estosterone Secretion Androxal • Androxal blocks estrogen at the level of the pituitary • Allows responsiveness to low T conditions • Leads to increased LH & FSH to stimulate normal testicular function • Increased LH and FSH levels T Hy

  10. Slide 10: FDA Recommendation for NDA May 9, 2012

    FDA Recommendation for NDA May 9, 2012 • Phase 3 pivotal studies to be conducted under SPA – 2 identical trials • 154 subjects in each trial (114 on Androxal , 38 on placebo) – Men with morning T<300 ng / dL assessed twice on two separate days • Up - titration from 12.5 to 25 • 3 month duration – Co

  11. Slide 11: Previous Androxal Experience

    Previous Androxal Experience ZA - 003 Testosterone Distribution (6 Month Data) 0 10 20 30 40 50 60 70 80 <300 300-400 400-800 >800 Testosterone Range (ng/dl) Percent of Patients 25 mg 12.5 mg Androgel Placebo n=162 patients

  12. Slide 12: Briefing Package Excerpt (Androxal data from ZA-204)

    Briefing Package Excerpt ( Androxal data from ZA - 204) Correlation of Morning T with 24 Hour Average & Tmax Androxal Arms Both correlations significant (p<0.0001) with a correlation coefficient of ~ 0.9

  13. Slide 13: ZA - End of Dosing Outcome

    ZA - 204 End of Dosing Outcome 0 200 400 600 800 1000 1200 Total T ng / dL End of Dosing Morning T Values 0 200 400 600 800 1000 1200 24 hour Avg. TT ( ng / dL ) 24 Hour Average T Values 0 500 1000 1500 2000 2500 3000 Maximum TT ( ng / dL ) Maximum Recorded T 6.25 mg 12.5 mg 25 mg Androgel Androgel

  14. Slide 14: Androxal Preserves Testicular Function

    Androxal Preserves Testicular Function Approved Topical Products Suppress the Hypothalamic - Pituitary - Testes Axis

  15. Slide 15: Androxal Subject Hour T & LH

    24 Hour T & LH 25 mg Androxal Subject Study ZA - 204 Subject 2 - 003 Age: 55, BMI: 32 0 2 4 6 8 10 12 14 16 0 100 200 300 400 500 600 700 800 0 5 10 15 20 T @ Baseline T @ 6 Weeks LH @ Baseline LH @ 6 Weeks Baseline 0 time: 8:09 AM Week 6 0 time: 7:25 AM

  16. Slide 16: Androgel Subject Hour T & LH

    24 Hour T & LH Androgel Subject Study ZA - 204 Subject 2 - 049 Age: 58 , BMI: 24.1 0 2 4 6 8 10 12 14 0 100 200 300 400 500 600 700 800 900 0 5 10 15 20 LH ( mIU /ml) Total Testosterone ( ng /dl) Hours T @ Baseline T @ 6 Weeks LH @ Baseline LH @ 6 Weeks Baseline 0 time: 7:31 AM Week 6 0 time: 6:19 A

  17. Slide 17: Mean Morning TT Over Time (ZA-204)

    0 100 200 300 400 500 600 700 Morning TT (ng/dL) Fig. 14: Mean Morning TT Over Time (ZA - 204) 6.25mg Androxal 12.5mg Androxal 25mg Androxal Androgel Week 2 Week 4 Week 6 Last Day of Dosing One Week Follow - up One week after dosing all Androxal arms were better than baseline One week after dosing t

  18. Slide 18: ZA - Hormone and Sperm Effects

    ZA - 203 Hormone and Sperm Effects Exogenous T Suppresses Pituitary Hormones and Testicular Function 0 2 4 6 8 10 12 14 12.5 mg 25 mg PL Testim FSH Treatment Effect of Treatment on Median FSH p versus Testim Before After p<0.00001 p=0.0004 0 10 20 30 40 50 60 70 80 90 100 12.5 mg 25 mg PL Testim [Sp

  19. Slide 19: Androxal Profile Favorable Compared to Leading T Products

    Androxal Profile Favorable Compared to Leading T Products T Gels/Creams Androxal Advantage Androxal Administration Applied to Skin Oral Controlled Substance Yes No Sexual Partner & Risk to Children Yes No Unpredictable Response Yes No Super High T Levels Yes No Prostate Risk Yes No Shuts Down Testes

  20. Slide 20: Third Party Study Indicates Favorable Reimbursement Potential for Androxal

    Third Party Study Indicates Favorable Reimbursement Potential for Androxal Majority of payers believe Androxal’s oral administration and non - chronic use may offer overall cost savings – Third party assessment of payers indicates vast majority (>90%) would add Androxal to formularies • Cost will be

  21. Slide 21: Androxal Take Home Message

    Androxal Take Home Message • Because of Obesity, 30% of American Males are at Risk of Secondary Hypogonadism – Co - morbidities include diabetes and cardiovascular disease • Approved T Products Worsen the Underlying Condition • Only Androxal + Diet + Exercise can reverse this disorder

  22. Slide 22: Proellex for the Treatment of Uterine Fibroids and Endometriosis

    Proellex for the Treatment of Uterine Fibroids and Endometriosis Over 30 million women of reproductive age in the US afflicted with symptomatic uterine fibroids or endometriosis Over 300,000 hysterectomies performed every year in the US to treat these two disorders No acceptable chronic therapeutic

  23. Slide 23: An Effective Dose of Proellex Stops Menstruation in Majority of Women

    An Effective Dose of Proellex Stops Menstruation in Majority of Women Proellex induced amenorrhea

  24. Slide 24: % of Women Experiencing Proellex Induced Amenorrhea in Low Dose Study

    % of Women Experiencing Proellex Induced Amenorrhea in Low Dose Study 0 10 20 30 40 50 60 70 80 90 100 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg Proposed Doses for Phase 3 Endometriosis Study Doses safely tested in Phase 2 trial

  25. Slide 25: Can a Low Dose Work?

    Can a Low Dose Work? Key Symptom Driving Women to Seek Therapy for Uterine Fibroids “Excessive Menstrual Bleeding” 0 20 40 60 80 100 120 140 160 BL Mo 1 Mo 2 Mo 3 PBAC Score Placebo Proellex 12.5 mg Proellex 25 mg US Phase IIb (n=127 ) P<0.0001 Menorrhagia =PBAC>80 Amenorrhea drives outcomes

  26. Slide 26: Proellex Produces Significant Clinical Benefit

    Proellex Produces Significant Clinical Benefit Resulting in Substantially Asymptomatic Uterine Fibroids UFSQOL Uterine Fibroid Symptom Survey p vs placebo < 0.0001 for both doses p vs placebo < 0.005 for both doses Spies et al, Obstetrics & Gynecology, vol. 99, No. 2, February 2002 Higher Score = Wo

  27. Slide 27: Patient Reported Endometriosis Pain

    Baseline vs Last 28 Days All Patient Reported Endometriosis Pain 0 10 20 30 40 50 60 70 Placebo Proellex 25mg Proellex 50 % of Baseline n=23 p - value versus placebo 25 mg = 0.001 50 mg = 0.017 n=20 n=21 Dysmenorrhea , Dyspareunia and Non Menstrual Pelvic Pain

  28. Slide 28: Doses That Stop Menses Impact Analgesic Use in Endometriosis

    Doses That Stop Menses Have Significant Impact on Analgesic Use in the Control of the Pain Symptoms of Endometriosis 88.9 33.4 36.4 0 10 20 30 40 50 60 70 80 90 100 Placebo 25mg Proellex 50mg Proellex % of Subjects Requiring Narcotic or Non Narcotic Analgesics at End of Study Baseline End of Study 5

  29. Slide 29: Vaginal Proellex to Eliminate the Need for Hysterectomy

    Vaginal Proellex to Eliminate the Need for Hysterectomy – New IND effective • Unaffected by oral outcomes – Initial Phase 2 study to test four doses of vaginal administration in the treatment of uterine fibroids • Assess reduction of fibroid size and elimination of symptoms • Company anticipates eff

  30. Slide 30: Systemic Exposure to Oral Proellex Varies in a Dose Dependent Manner

    Systemic Exposure to Oral Proellex Varies in a Dose Dependent Manner Significant reduction in exposure via vaginal delivery 0 200 400 600 800 1000 1200 1400 1600 1800 12 mg vaginal 1 mg 3 mg 6 mg 9 mg 12 mg 25 mg 50 mg Concentration ( ng /ml) Combined Cmax for Telapristone and Primary Metabolite Liv

  31. Slide 31: Early Efficacy Signal Detected for Proellex-V

    Early Efficacy Signal Detected for Proellex - V 0 25 50 75 100 125 150 175 200 225 250 275 PBAC Score Baseline Cycle 1 Menorraghia PBAC=80 0 10 20 30 40 50 60 70 80 90 UFSQOL Score Baseline Cycle 1 Normal Score for Women w/o fibroids Steady State Drug Concentrations Subject 1: 14.2 ng /ml Subject 2:

  32. Slide 32: Proellex-V Slow to Reach Steady State

    Proellex - V Slow to Reach Steady State 0 2 4 6 8 10 12 14 16 18 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 Day 13 Day 14 Total Parent + Metabolite ( ng /ml) Average Daily Trough Levels

  33. Slide 33: At Steady State Proellex-V Yields Flat Exposure Profile

    At Steady State Proellex - V Yields Flat Exposure Profile 0 100 200 300 400 500 600 0 4 8 12 16 20 24 Conc. (ng/ml) Time (Hr) Average: PK Oral (1, 3, 6, 9 and 12 mg vs Vaginal 12 mg) 1 mg oral 3 mg oral 6 mg oral 9 mg oral 12 mg oraql 12 mg vaginal

  34. Slide 34: Rabbit anti-Clauberg Study

    Control 12.5 mg oral equivalent 50 mg oral equivalent 12.5 mg vaginal equivalent 50 mg vaginal equivalent Rabbit anti - Clauberg Study

  35. Slide 35: Increasing Oral Dose Continues to Shrink Fibroids

    Increasing Oral Dose Continues to Shrink Fibroids Repros Expects Vaginal Delivery to Exceed Shrinkage Effects of Highest Oral Dose Tested 0 10 20 30 40 50 60 70 80 90 100 Baseline 3 month treatment @ 25mg 4 month treatment @ 50mg Four women initially treated for 3 months at 25 mg dose Follow - up st

  36. Slide 36: Financial Summary

    Financial Summary • Cash and equivalents (as of 6/1/12, unaudited) ~ $10.8M • Cash burn = 2012 = ~$12 M) • Cash runway = Q2 2013 • 14.82 MM shares outstanding – Warrants outstanding = 1.75MM Series A (Purchased in unit deal @$2.46) + 1.69MM Series B (@$2.49 with cashless exercise provision) – Forced

  37. Slide 37: Recently Completed & Upcoming Milestones

    Recently Completed & Upcoming Milestones • Reported results for two Phase 2 Androxal Studies Q4 - 11 • Reported results for low dose Phase 2 Proellex Study Q4 - 11 • Reported effective IND for Vaginal Proellex Phase 2 Q1 - 12 • Commence Dosing Phase 2 UF Vaginal Proellex Q1 - 12 • Held Meeting with

Repros Therapeutics — Investor Presentation (June 2012) on 6ix